Sangamo Therapeutics Inc [NASDAQ: SGMO] loss -1.64% or -0.01 points to close at $0.74 with a heavy trading volume of 6349527 shares.
The daily chart for SGMO points out that the company has recorded -11.83% loss over the past six months.
If we look at the average trading volume of 6.63M shares, SGMO reached to a volume of 6349527 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Sangamo Therapeutics Inc [SGMO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SGMO shares is $5.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SGMO stock is a recommendation set at 1.71. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Sangamo Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 13, 2024. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on December 10, 2024, representing the official price target for Sangamo Therapeutics Inc stock. Previously, the target price had yet another drop from $6 to $2, while RBC Capital Mkts kept a Sector Perform rating on SGMO stock. On April 28, 2023, analysts decreased their price target for SGMO shares from 5 to 1.50.
The Average True Range (ATR) for Sangamo Therapeutics Inc is set at 0.10, with the Price to Sales ratio for SGMO stock in the period of the last 12 months amounting to 2.87. The Price to Book ratio for the last quarter was 6.90, with the Price to Cash per share for the same quarter was set at 0.19.
Trading performance analysis for SGMO stock
Sangamo Therapeutics Inc [SGMO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.59. With this latest performance, SGMO shares dropped by -26.91% in over the last four-week period, additionally sinking by -11.83% over the last 6 months – not to mention a rise of 35.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SGMO stock in for the last two-week period is set at 45.01, with the RSI for the last a single of trading hit 49.10, and the three-weeks RSI is set at 43.02 for Sangamo Therapeutics Inc [SGMO]. The present Moving Average for the last 50 days of trading for this stock 0.9279, while it was recorded at 0.7252 for the last single week of trading, and 1.1760 for the last 200 days.
Sangamo Therapeutics Inc [SGMO]: A deeper dive into fundamental analysis
Sangamo Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.13 and a Current Ratio set at 1.13.
An analysis of Institutional ownership at Sangamo Therapeutics Inc [SGMO]
There are presently around $27.54%, or 28.14%% of SGMO stock, in the hands of institutional investors. The top three institutional holders of SGMO stocks are: WASATCH ADVISORS LP with ownership of 20.09 million shares, which is approximately 9.8509%. ARMISTICE CAPITAL, LLC, holding 14.06 million shares of the stock with an approximate value of $$5.04 million in SGMO stocks shares; and ARMISTICE CAPITAL, LLC, currently with $$4.26 million in SGMO stock with ownership which is approximately 6.5977%.
